Epigenetic regulation of gfi1 in endocrine-related cancers: A role regulating tumor growth
Entity
UAM. Departamento de MedicinaPublisher
MDPI, Basel, SwitzerlandDate
2020-06-30Citation
10.3390/ijms21134687
International Journal of Molecular Sciences 21.13 (2020): 4687
ISSN
1422-0067DOI
10.3390/ijms21134687Funded by
This research was funded by Grants from the Fondo de Investigaciones Sanitarias, of the Instituto de Salud Carlos III (PI11/608 and PI16/594).Project
Gobierno de España. PI11/608; Gobierno de España. PI16/594Editor's Version
https://doi.org/10.3390/ijms21134687Subjects
Breast cancer; DNA methylation; Gfi1; Prostate cancer; MedicinaRights
© 2020 The authorsAbstract
Prostate and breast cancer constitute the most common cancers among men and women worldwide. The aging population is one of the main risk factors for prostate and breast cancer development and accumulating studies link aging with epigenetic changes. Growth factor independence-1 (Gfi1) is a transcriptional repressor with an important role in human malignancies, including leukemia, colorectal carcinoma, and lung cancer, but its role in prostate and breast cancer is unknown. We have found that Gfi1 epigenetic silencing is a common event in prostate and breast cancer. Gfi1 re-expression in prostate and breast cancer cell lines displaying Gfi1 epigenetic silencing decreases cell proliferation, reduced colony formation density, and tumor growth in nude mice xenografts. In addition, we found that Gfi1 repress alpha 1-anti-trypsin (AAT) and alpha 1-anti-chymotrypsin (ACT) expression, two genes with important functions in cancer development, suggesting that Gfi1 silencing promotes tumor growth by increasing AAT and ACT expression in our system. Finally, Gfi1 epigenetic silencing could be a promising biomarker for prostate cancer progression because it is associated with shorter disease-free survival. In conclusion, our findings strongly indicate that Gfi1 epigenetic silencing in prostate and breast cancer could be a crucial step in the development of these two-well characterized endocrine related tumors.
Files in this item
Google Scholar:Ashour, Nadia
-
Angulo, Javier C.
-
González-Corpas, Ana
-
Orea, María J.
-
Lobo, María V.T.
-
Colomer Bosch, Ramón
-
Colás, Begoña
-
Esteller, Manel
-
Ropero, Santiago
This item appears in the following Collection(s)
Related items
Showing items related by title, author, creator and subject.
-
Follow-up study confirms the presence of gastric cancer DNA Methylation Hallmarks in high-risk precursor lesions
Gómez, Antonio; Pato, Miguel L.; Bujanda, Luis; Sala, Núria; Companioni, Osmel; Cosme, Ángel; Tufano, Martina; Hanly, David J.; García, Nadia; Sanz-Anquela, José Miguel; Pérez Gisbert, Francisco Javier; López, Consuelo; Elizalde, José Ignacio; Cuatrecasas, Miriam; Andreu, Victoria; Paules, María José; Martín Arranz, María Dolores; Ortega, Luis; Poves, Elvira; Barrio, Jesús; Torres, María Ángeles; Muñoz, Guillermo; Ferrández, Ángel; Ramírez-Lázaro, María José; Lario, Sergio; González, Carlos A.; Esteller, Manel; Berdasco, María
2021-06-02 -
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
Quintela Fandiño, Miguel Ángel; Holgado, Esther; Manso, Luis; Morales, Serafin; Bermejo, Begoña; Colomer Bosch, Ramón; Apala, Juan V.; Blanco, Raquel; Muñoz, Manuel; Caleiras, Eduardo; Iranzo, Vega; Martinez, Mario; Dominguez, Orlando; Hornedo, Javier; Gonzalez-Cortijo, Lucia; Cortes, Javier; Gasol Cudos, Ariadna; Malon, Diego; Lopez-Alonso, Antonio; Moreno-Ortíz, María C.; Mouron, Silvana; Mañes, Santos
2020-12-01 -
Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies
Rogado, Jacobo; Romero-Laorden, Nuria; Sanchez-Torres, José Miguel; Ramos-Levi, Ana María; Pacheco-Barcia, Vilma; Ballesteros, Ana Isabel; Arranz, Reyes; Lorenzo, Alicia; Gullon, Pedro; Garrido, Ana; Serra López-Matencio, José María; Donnay, Olga; Adrados, Magdalena; Costas, Pablo; Aspa Marco, Francisco Javier; Alfranca González, Arantzazu; Mondejar, Rebeca; Colomer Bosch, Ramón
2020-04-16